Nov 5, 2019 — 3 min read
Lunit has announced Korea MFDS (Ministry of Food and Drug Safety) approval of its AI solution for chest x-ray, Lunit INSIGHT CXR 2. The medical software has been approved on October 21st, which marks the third approval of its AI solution by Korea MFDS.
Lunit INSIGHT CXR 2, which is now available for domestic sales in Korea, runs on Lunit’s proprietary AI technology, co-developed with one of the most prestigious Korean medical institutions--Seoul National University Hospital.
The software analyzes chest x-ray images within seconds, providing an indication of the location of lesions suspicious for major lung abnormalities such as nodule, consolidation, and pneumothorax. An abnormality score of the detected lesion is also shown with the location information.
According to Lunit, INSIGHT CXR 2 is an upgraded version of INSIGHT CXR 1, which had received Korea MFDS clearance last year. The earlier version detects the nodule only, whereas INSIGHT CXR 2 is equipped with an extended list of detectable abnormalities.
“Lunit INSIGHT CXR was designed to assist doctors with faster and more accurate diagnosis,” said Brandon Suh, CEO of Lunit. “We are continuously expanding the scope of our chest x-ray products by adding more detection feature to Lunit INSIGHT CXR series. Our most advanced technology detects 10 major lung findings, and we hope to be able to present this to our customers soon,” added Suh.
“In the meantime, regulatory approval of Lunit INSIGHT CXR 2 is exciting news for us, as the product can be applied in real-world clinical settings and prove itself to be helpful in daily routine chest x-ray screening and diagnosis, especially for lung cancer, pneumonia, tuberculosis, and pneumothorax.”
In the course of the development of the product, Lunit has been writing papers showing the findings obtained during the course of algorithm development, and successfully published them in major medical publications such as Radiology, Clinical Infectious Diseases, JAMA Network Open, and etc.
The earlier version of the software had previously received MFDS clearance last year in August. The software is currently being used at multiple hospitals and medical examination centers throughout the country, including Seoul National University Hospital, medical check-up centers, and public health clinics.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?